DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM
Complete Response Rate of 42% as Assessed by Principal Investigator Supports VAL-082’s Activity in GBM VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 20, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)… Read More